Pictet Asset Management (UK)’s BridgeBio Pharma BBIO Stock Holding History

Pictet Asset Management (UK)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$4.25M	Buy	69,687 +66,252	+1,929%	+$3.78M	﹤0.01%	889
2021 Q1	$212K	Buy	+3,435	New	+$225K	﹤0.01%	1654
2019 Q4	–	Sell	-61,511	Closed	-$1.32M	–	1112
2019 Q3	$1.32M	Sell	61,511 -38,562	-39%	-$1.07M	﹤0.01%	901
2019 Q2	$2.7M	Buy	+100,073	New	+$2.73M	0.01%	823

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Pictet Asset Management (UK)'s BBIO Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its BridgeBio Pharma (BBIO) stake by 1,929% in Q2 2021, buying an estimated $3.78M and bringing the position to 69,687 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #889.

Pictet Asset Management (UK) first reported a position in BBIO in Q2 2019 and has held it in 4 quarters since. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

Pictet Asset Management (UK) held 69,687 shares of BridgeBio Pharma worth $4.25M as of Q2 2021.
Pictet Asset Management (UK) bought 66,252 BridgeBio Pharma shares in Q2 2021, an estimated $3.78M.
BridgeBio Pharma made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #889 holding.
Pictet Asset Management (UK) first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 4 quarters since.
200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.